Nov 2, 2023 7:00 am EDT Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
Oct 30, 2023 7:00 am EDT Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program
Oct 9, 2023 7:00 am EDT Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®
Sep 21, 2023 8:00 am EDT Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference
Sep 7, 2023 8:00 am EDT Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference
Aug 16, 2023 6:00 am EDT Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals
Aug 10, 2023 4:05 pm EDT Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update
Aug 9, 2023 8:00 am EDT Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference